Chronic Hepatitis B Virus Infection
Conditions
Keywords
Ropeginterferon alpha-2b, Hepatitis B, Entecavir, HBeAg-negative, Nucleoside Analogue Therapy
Brief summary
This is an open-label, multicenter, randomized, active control study, comparing P1101 monotherapy to entecavir monotherapy in patients with HBeAg-negative chronic hepatitis B under long-term nucleos(t)ide analogue therapy.
Detailed description
Eligible patients will be randomized in a 2:1 ratio (P1101 monotherapy vs. Entecavir monotherapy) using a computer-generated permuted block randomization scheme. Subjects will be treated with 450 µg of P1101 every two weeks or with 0.5 mg of Entecavir monotherapy once per day. Primary endpoint will be evaluated at week 48. Subjects will receive treatment with a total duration of 72 weeks. The follow-up (treatment-free) period is 24 weeks following completion of treatment. Switch from the other nucleos(t)ide analogue therapy to entecavir will occur at week 0 (Randomization), while the dose of Entecavir will be 0.5 mg.
Interventions
Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
DRUGEntecavir
Entecavir 0.5 mg once per day
Sponsors
PharmaEssentia
National Taiwan University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adults with age 20-75 years old; Subjects who are over 70 years of age must be in generally good health; * Confirmed diagnosis of chronic hepatitis B (CHB) virus infection: with positive HBsAg ≧ 6 months prior to the study entry; * Quantitative HBsAg level \< 1,500 IU/ml at screening; * Confirmed HBeAg (-) at screening; * Stable disease: ALT \< 3 x upper limit of normal (ULN), total bilirubin \< 1.5 × ULN (except in Gilbert syndrome) and direct bilirubin \< ULN at screening, serum HBV DNA \< 50 IU/mL for ≧ 1 year prior to study entry; * Stable treatment with nucleos(t)ide regimen (adefovir, entecavir, tenofovir or one of the following combinations: entecavir/adefovir or entecavir/tenofovir) for at least 2 years prior to study entry; * Interferon treatment naïve; * Normal fundoscopic examination by ophthalmologist at screening; defined as no significant or major fundoscopic findings including but not limited to retinal exudates, hemorrhage, detachment, neovascularization, papilloedema, optic atrophy, microaneurysms and macular changes; * Be able to attend all scheduled visits and to comply with all study procedures; * Be able to provide written informed consent.
Exclusion criteria
* HBeAg-positive chronic hepatitis B; * Documented history of drug resistance to any nucleoside/ nucleotide analogue; * History of treatment with lamivudine or telbivudine prior to the study entry; * Clinically significant abnormalities, other than HBV infection, based upon the results of a medical history, physical examination, vital signs, and a 12-lead electrocardiogram (ECG) at screening as determined by the investigator; * Other form of significant chronic liver disease apart from chronic hepatitis B infection; Severe steatohepatitis by ultrasound or other examinations at the discretion of investigators; * Liver cirrhosis; * Known positive for anti-HIV; * Positive for anti-hepatitis C virus(HCV), Subject could be enrolled if no HCV RNA detected within 1 year； * Co-infection with hepatitis D; * One of clinically significant abnormal laboratory test result at screening: white blood cell (WBC) \< 3,000/mm\^3, absolute neutrophil count (ANC) \< 1500/mm\^3, Hgb \< 10g/dL, platelet \< 90,000/mm\^3, estimated Glomerular filtration rate \< 60 mL/min; * History of significant alcohol or illicit drug abuse within six months prior to the screening visit (alcohol consumption of more than fourteen units of alcohol per week \[1 Unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol\]) or refusal to abstain from illicit drugs and minimize alcohol consumption throughout the study; * History of severe allergic or hypersensitivity reactions (e.g bronchospasm, angioedema), asthma, or anaphylaxis * Therapy with any systemic anti-viral treatment (except for treatment for HBV), anti-neoplastic, immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) and immunosuppressants within 1 month (3 months for those with long elimination half-lives) prior to the first dose of study drug; * Use of an investigational drug within the last 4 weeks; * Any history or presence of poorly controlled or clinically significant medical conditions that are not suitable to receive interferon-based treatment, at the discretion of the investigator: major psychiatric (including but not limited to those with severe depression, severe bipolar disorder, schizophrenia, suicidal ideation or history of suicidal attempt),neurological, cardiovascular (e.g. uncontrolled hypertension), pulmonary (including but not limited to chronic obstructive lung disease), hematological, immunologic, endocrine, metabolic (e.g. diabetes mellitus with HbA1C \> 8.0%), autoimmune disease, thyroid or other uncontrolled systemic disease, coagulation disorders or blood dyscrasias; * A depot injection or an implant of any drug within 3 months prior to administration of study medication, other than contraception or hyaluronic acid injections in joints for osteoarthritis; * History of solid organ transplantation; * History of malignancy diagnosed or treated within 5 years prior to screening (except for recent localized treatment of squamous or noninvasive basal cell skin cancers; cervical carcinoma in situ), cancer survivors not on maintenance therapy within the past 5 years; * History of opportunistic infection (e.g., invasive candidiasis or pneumocystis pneumonia) * Serious localized infection (e.g., cellulitis, abscess) or systemic and life-threatening infection (e.g., septicemia) within the 3 months prior to screening; * Pregnant subjects. Female subjects or the spouse of male subjects, with child-bearing potential who are unwilling or unable to practice adequate contraception, defined as vasectomy in men, tubal ligation in women, or use of condoms and spermicides, or birth control pills, or intrauterine devices from 4 weeks prior to Day 1 until 90 days after the last dose of study drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Undetectable HBsAg | Week 48 | HBsAg loss at week 48 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Undetectable HBsAg | weeks 72 and 96 | HBsAg loss at weeks 72 and 96 |
| HBsAg and anti-HBs level | weeks 48, 72 and 96 | HBsAg seroconversion at weeks 48, 72 and 96 |
| Reappearance of HBsAg | weeks 72 and 96 | HBsAg seroreversion at weeks 72 and 96 |
| HBsAg level | weeks 12, 24, 48, 72 and 96 | HBsAg reduction \> 1 log from baseline to weeks 12, 24, 48, 72 and 96 |
| HBV DNA and alanine aminotransferase (ALT) level | week 96 | Percentage of subjects with HBV DNA \> 2,000 IU/ml and ALT \> 2x ULN at week 96 |
| Sustained suppression of HBV DNA | week 96 | Sustained suppression of HBV DNA less than the lower limit of qualification at week 96. |
| HBeAg level | weeks 72 and 96 | To compare the proportion of HBeAg seroreversion and seroconversion at weeks 72 and 96 across treatment arms. |
| HBV DNA level | week 96 | Percentage of subjects with HBV DNA \> 2,000 IU/ml at week 96 |
Countries
Taiwan
Contacts
Primary ContactChun-Jen Liu
Outcome results
None listed